C12N 2830/20
Transcription of more than one cistron
Official title: transcription of more than one cistron
C12N2830/20 (Transcription of more than one cistron) appears on 124 US grants and 252 published applications in this corpus.
Search patents in C12N- Granted patents
- 124
- Published applications
- 252
- Assignees
- 170
- Inventors
- 552
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 3 |
| 2003 | 1 | 6 |
| 2004 | 1 | 5 |
| 2005 | 4 | 5 |
| 2006 | 1 | 4 |
| 2007 | 2 | 6 |
| 2008 | 2 | 6 |
| 2009 | 2 | 4 |
| 2010 | 1 | 7 |
| 2011 | 4 | 8 |
| 2012 | 4 | 6 |
| 2013 | 1 | 8 |
| 2014 | 4 | 11 |
| 2015 | 6 | 10 |
| 2016 | 3 | 7 |
| 2017 | 9 | 8 |
| 2018 | 6 | 12 |
| 2019 | 6 | 11 |
| 2020 | 10 | 14 |
| 2021 | 9 | 25 |
| 2022 | 4 | 13 |
| 2023 | 16 | 22 |
| 2024 | 5 | 13 |
| 2025 | 11 | 19 |
| 2026 | 6 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance26 May 2026US 12,637,690 B2eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance19 May 2026US 12,630,838 B2eGenesis, Inc.
- Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion5 May 2026US 12,617,832 B2Ramot at Tel-Aviv University Ltd.
- Compositions and methods for anti-TnMUC1 gold CAR t-cells17 Mar 2026US 12,576,135 B2Chimera Bioengineering, Inc.
- Optimized expression cassettes for gene therapy3 Mar 2026US 12,564,647 B2Tenaya Therapeutics, Inc.
- Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion17 Sep 2026US 2026/0274916 A1Ramot at Tel-Aviv University Ltd.
- Rna directed method to produce mature retinal pigment epithelial cells for transplantation10 Sep 2026US 2026/0265688 A1The Regents of the University of California
- Methods and materials for treating prader-willi syndrome27 Aug 2026US 2026/0248959 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Cd19-specific antibody constructs and compositions thereof30 Jul 2026US 2026/0217822 A1
- Methods and systems for engineering cells and for target validation30 Jul 2026US 2026/0218150 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- DNA transfection system for the generation of infectious influenza virus91US 6,951,754 B2St. Jude Children?S Research Hospital · 2005
- Multicistronic expression constructs63US 9,546,369 B2University of Massachusetts · 2017
- DNA transfection system for the generation of infectious influenza virus45US 7,312,064 B2St. Jude Children's Research Hosptal · 2007
- DNA-transfection system for the generation of infectious influenza virus41US 7,972,843 B2St. Jude Children?S Research Hospital · 2011
- Antigen delivery platforms37US 11,078,237 B2Glaxosmithkline Biologicals SA · 2021